IP Library Granted Patent US 12,540,325
Granted Patent B2
US 12,540,325 · App. 18/621,742 · Granted Feb 3, 2026

RNase inhibitors

Inventors: Nathan Tanner (West Newbury, MA); Jennifer Ong (Salem, MA); Esta Slayton (Epping, NH); Lisa L. Maduzia (Topsfield, MA); Salvatore V. Russello (Newbury, MA)
Assignee: New England Biolabs, Inc.
C12N15/1137C12N9/1247C12N9/1276C12N15/1003C12Q1/6848C12N9/58C12N2310/16C12Y207/07006C12Y207/07049
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,540,325
App. No.
18/621,742
Granted
Feb 3, 2026
Kind
B2
Abstract

Compositions, methods and kits are provided that include an inhibitory oligonucleotide RNase inhibitor capable of inhibiting one or more types of RNase that coexist with biological samples or are introduced in the laboratory, thereby protecting RNA in the sample from degradation. More than one type of oligonucleotide RNase inhibitor may be combined in a mixture to inhibit a plurality of different RNases. Single oligonucleotides were identified to have inhibitory activity for a plurality of different RNases. The RNase oligonucleotide inhibitor may be immobilized on beads or other surface. It may be stored in a lyophilized form or in solution.

Claims (17)

1 . A method, comprising:

(a) combining an aptamer composition comprising: one or more single stranded oligonucleotides that bind to at least one RNAse selected from RNase A and RNase I,

wherein the one or more single stranded oligonucleotides are selected from:

an oligonucleotide having at least 90% sequence identity with a sequence selected from any of SEQ ID NOs: 1-62; and

an oligonucleotide having at least 90% sequence identity with a sequence selected from any of SEQ ID NOs: 1-62, further comprising one or more hydrophobic nucleotide substitutions in the oligonucleotide, and

wherein the one or more single stranded oligonucleotides are immobilized on a matrix;

and a sample comprising RNA and the at least one RNase,

(b) separating the immobilized oligonucleotides from the sample, thereby depleting the at least one RNase from the sample to produce a depleted sample;

(c) contacting the depleted sample with a reverse transcriptase and reverse transcribing the RNA to form DNA, and

(d) amplifying the DNA for subsequent detection, purification or sequencing.

2 . The method of claim 1 , wherein the matrix is beads.

3 . The method of claim 2 , wherein the beads are streptavidin beads.

4 . The method of claim 3 , wherein the one or more aptamers are biotinylated aptamers.

5 . The method of claim 2 , wherein the beads are magnetic beads.

6 . The method of claim 1 , wherein the sample comprises a biological sample selected from urine, saliva, blood, and serum.

7 . The method of 1 , wherein the one or more hydrophobic nucleotide substitutions are selected from 5-(N-benzylcarboxyamide)-dUTP (BndUTP), 5-(N-isobutylcarboxyamide)-dUTP (iBudUTP), 5-(N-tryptaminocarboxyamide)-dUTP (Trp dUTP), and Napthyl-dU.

8 . The method of claim 1 , wherein the DNA is amplified using LAMP or PCR.

Assignments (2)
SECURITY INTEREST Recorded May 29, 2026
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 074795/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 11, 2024
From: TANNER, NATHAN; ONG, JENNIFER; SLAYTON, ESTA; MADUZIA, LISA; RUSSELLO, SALVATORE V.
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 067074/0234 →
Continuity (5)
Continuation 18509899 · Nov 15, 2023
Continuation 17207507 · Mar 19, 2021
Provisional Application 63001417 · Mar 29, 2020
Provisional Application 62992921 · Mar 21, 2020
Related Publication 20240229040A1 · Jul 11, 2024
References Cited (11)
US 8975388B2 · Zichi et al. · 2015 [cited by applicant]
US 10633644B1 · Chen et al. · 2020 [cited by applicant]
US 20100240550A1 · Jackson · 2010 [cited by applicant]
US 20130137090A1 · Nussbaum · 2013 [cited by examiner]
US 20180289464A1 · Kassab · 2018 [cited by examiner]
WO WO2005083081A1 · 2005 [cited by examiner]
Tuerk, et al (1990), Science 249 p. 505-10. [cited by applicant]
Blackwell, et al. (1990) Science 250 1104-10. [cited by applicant]
Gold et al.. 2010. PLoS One vol. 5. [cited by applicant]
Stoltenburg, et al. (2015) PLOS One vol. 10. [cited by applicant]
Wu, et al (2016), Methods 106, 21-28. [cited by applicant]